Your browser is no longer supported. Please, upgrade your browser.
ILMN Illumina, Inc. daily Stock Chart
Illumina, Inc.
IndexS&P 500 P/E40.38 EPS (ttm)5.08 Insider Own0.60% Shs Outstand146.52M Perf Week-4.20%
Market Cap30.03B Forward P/E46.48 EPS next Y4.41 Insider Trans-24.31% Shs Float145.02M Perf Month8.26%
Income747.70M PEG2.73 EPS next Q0.99 Inst Own94.50% Short Float2.62% Perf Quarter16.91%
Sales2.49B P/S12.08 EPS this Y0.90% Inst Trans-1.23% Short Ratio4.06 Perf Half Y25.35%
Book/sh18.60 P/B11.02 EPS next Y20.76% ROA16.60% Target Price186.21 Perf Year18.37%
Cash/sh12.92 P/C15.86 EPS next 5Y14.78% ROE30.80% 52W Range119.37 - 214.34 Perf YTD60.07%
Dividend- P/FCF56.80 EPS past 5Y38.00% ROI14.00% 52W High-4.38% Beta0.77
Dividend %- Quick Ratio3.40 Sales past 5Y17.80% Gross Margin67.00% 52W Low71.69% ATR3.71
Employees5500 Current Ratio3.90 Sales Q/Q10.30% Oper. Margin20.10% RSI (14)56.93 Volatility1.53% 1.88%
OptionableYes Debt/Eq0.43 EPS Q/Q6.90% Profit Margin30.10% Rel Volume1.11 Prev Close209.40
ShortableYes LT Debt/Eq0.43 EarningsAug 01 AMC Payout0.00% Avg Volume937.35K Price204.95
Recom2.40 SMA200.59% SMA507.21% SMA20019.95% Volume1,040,877 Change-2.13%
Aug-07-17Upgrade Canaccord Genuity Hold → Buy $170 → $215
Aug-02-17Upgrade First Analysis Sec Underweight → Equal-Weight
Apr-26-17Reiterated Cantor Fitzgerald Neutral $155 → $170
Mar-20-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-01-17Reiterated UBS Buy $180 → $185
Jan-18-17Initiated Deutsche Bank Hold $160
Jan-10-17Upgrade BofA/Merrill Neutral → Buy
Jan-06-17Upgrade CL King Neutral → Buy
Dec-07-16Reiterated Morgan Stanley Underweight $115 → $100
Nov-10-16Resumed Leerink Partners Mkt Perform
Nov-02-16Downgrade First Analysis Sec Equal-Weight → Underweight $130 → $116
Oct-11-16Reiterated Cantor Fitzgerald Hold $165 → $155
Oct-11-16Reiterated Canaccord Genuity Hold $165 → $136
Oct-11-16Downgrade Citigroup Buy → Neutral
Aug-22-16Downgrade CL King Buy → Neutral
Jul-27-16Reiterated Mizuho Neutral $138 → $148
Jul-05-16Downgrade Morgan Stanley Equal-Weight → Underweight $130 → $110
Jun-22-16Initiated CL King Buy
May-04-16Reiterated Stifel Buy $215 → $160
May-04-16Reiterated Mizuho Neutral $150 → $138
Sep-19-17 07:15AM  3 Innovation-Forward Healthcare Stocks to Buy Now Motley Fool
Sep-14-17 06:25PM  ETFs with exposure to Illumina, Inc. : September 14, 2017 Capital Cube
Sep-13-17 11:36AM  Illumina, Inc. :ILMN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 Capital Cube
Sep-11-17 10:06AM  See what the IHS Markit Score report has to say about Illumina Inc. Markit
Sep-07-17 11:47AM  Why Illumina Rose 18.7% in August Motley Fool
09:00AM  Illumina Files New Patent Infringement Suit Against Premaitha Health plc Business Wire
Aug-29-17 08:05AM  See what the IHS Markit Score report has to say about Illumina Inc. Markit
Aug-28-17 08:04AM  See what the IHS Markit Score report has to say about Illumina Inc. Markit
Aug-27-17 08:02AM  These 3 Stocks Are Priced for Perfection. Can They Deliver? Motley Fool
Aug-25-17 02:43PM  3 Reasons Exact Sciences Is a Better Growth Stock Than Illumina Motley Fool
09:47AM  Illumina Teams Up With Telegraph Hill to Form Verogen Zacks
Aug-24-17 09:00AM  Illumina and Telegraph Hill Partners Launch Verogen, Inc. to Drive Adoption of Next-Generation Sequencing in the Global Forensic Genomics Market Business Wire
Aug-22-17 08:02AM  See what the IHS Markit Score report has to say about Illumina Inc. Markit
Aug-21-17 08:02AM  See what the IHS Markit Score report has to say about Illumina Inc. Markit
Aug-18-17 07:47AM  These 5 underloved stocks are hidden gems MarketWatch
Aug-17-17 08:04AM  See what the IHS Markit Score report has to say about Illumina Inc. Markit
Aug-16-17 06:27PM  High-profile investors, including Laurene Powell Jobs, just put $80 million into Color Genomics CNBC
08:03AM  See what the IHS Markit Score report has to say about Illumina Inc. Markit
Aug-15-17 05:35PM  One Company That's Set to Win From Precision Medicine Motley Fool
07:00AM  Earnings Review and Free Research Report: Illumina Reported Better Than Expected Revenue and Earnings Results ACCESSWIRE
Aug-14-17 08:53AM  The Best Marijuana and Precision Medicine Stocks to Buy Might Not Be the Companies You Think Motley Fool
08:02AM  See what the IHS Markit Score report has to say about Illumina Inc. Markit
Aug-13-17 11:32AM  Your Genome May Become the Next Facebook Motley Fool
Aug-12-17 08:31AM  Edited Transcript of ILMN earnings conference call or presentation 1-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 08:03AM  IHS Markit Score downgrades Illumina Inc to 32 out of 100, ranking positively in only one out of three available IHS Markit categories. Markit
Aug-09-17 08:02AM  Illumina Introduces a New Genomic Era Motley Fool
07:00AM  Azumio Introduces DNA-Based Insights into its Fitness Platform PR Newswire
Aug-08-17 05:54PM  Illumina, Inc. Value Analysis (NASDAQ:ILMN) : August 8, 2017 Capital Cube
Aug-07-17 02:49PM  Illumina Now A Buy Following Q2 Beat, Improved Sales Outlook Benzinga
11:40AM  Is Illumina Stock a Buy at Nearly 40 Times Earnings? 1 Analyst Thinks So Motley Fool
Aug-05-17 10:50AM  Doctors say this start-up could revolutionize how we fight infectious diseases CNBC
Aug-04-17 08:50AM  Illumina (ILMN) Rides on New Products, Low Margin a Concern Zacks
Aug-03-17 09:31PM  Illumina vs. Intuitive Surgical: Which Company Reported Better Earnings? Motley Fool
08:28PM  ETFs with exposure to Illumina, Inc. : August 4, 2017 Capital Cube
11:18AM  Illumina Beats In Q2, But Investment Thesis Remains Unclear Benzinga
09:02AM  Pacific Biosciences of California Struggles in the Second Quarter With Lower Sales Motley Fool
08:56AM  Illumina (ILMN) Catches Eye: Stock Soars 14.8% Zacks
12:30AM  Asia shares fall as Apple's glossy earnings effect fades Associated Press
Aug-02-17 11:25PM  Asia shares fall as Apple's glossy earnings effect fades Associated Press +14.83%
04:33PM  Why Illumina, Spirit AeroSystems Holdings, and Frontier Communications Jumped Today Motley Fool
04:31PM  New iPhone Fears 'Overblown'; Illumina Upgraded, Stock Breaks Out Investor's Business Daily
04:28PM  Apple, Illumina rise; AMC Entertainment, GGP fall Associated Press
04:16PM  The Hot Stock: Illumina Roars 15% Higher
03:42PM  10 Reasons Illumina's Momentum Is Just Cranking Up Motley Fool
02:30PM  Nasdaq Erases Losses, Illumina Breaks Out; Is It Still OK To Buy Apple? Investor's Business Daily
02:05PM  UPDATE 1-Illumina shares sparkle on strong demand for new gene tech Reuters
12:22PM  Illumina Soars After Crushing Expectations for Q2 Motley Fool
12:17PM  Will Illumina Maintain This Feverish Pace? Chart Shows What's Next
11:17AM  Illumina Shares Spike on Strong Earnings, Upside Still Remains: Biotech Movers
11:04AM  Illumina shares sparkle on demand for new gene tech Reuters
10:25AM  Illumina (ILMN) Tops Q2 Earnings & Revenues, Raises View Zacks
09:50AM  Stocks Open Higher: Apple Breaks Out, Dow Clears 22,000 Investor's Business Daily
08:03AM  Illumina Inc. Blows Past Guidance in Second Quarter With Strong NovaSeq Demand Motley Fool
07:51AM  Early movers: MDLZ, AAPL, WMT, CAH, GRMN, AN, FEYE, VZ & more CNBC
Aug-01-17 10:56PM  Illumina tops Street 2Q forecasts Associated Press
05:38PM  After-hours buzz: APPL, FEYE & more CNBC
05:38PM  Illumina shares rally as revenue tops Street view MarketWatch
04:39PM  Illumina beats on top line CNBC Videos
04:05PM  Illumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 Business Wire
11:15AM  Investor Network: Illumina, Inc. to Host Earnings Call ACCESSWIRE
12:01AM  Kindara Unveils Plan To Revolutionize Women's Health Industry With Kindara DNA PR Newswire
Jul-27-17 08:25AM  Illumina, Inc. breached its 50 day moving average in a Bullish Manner : ILMN-US : July 27, 2017 Capital Cube
Jul-24-17 04:41PM  ETFs with exposure to Illumina, Inc. : July 24, 2017 Capital Cube
08:39AM  Can Illumina (ILMN) Spring a Surprise this Earnings Season? Zacks
07:50AM  Helix: An 'app' store for your DNA CNBC Videos
07:30AM  Helix Bets An 'App Store' Can Make Consumers Care About Their DNA Forbes
Jul-21-17 07:15AM  7 Near-Monopolies That Are Perfectly Legal in America Motley Fool
Jul-14-17 03:04PM  ETFs with exposure to Illumina, Inc. : July 14, 2017 Capital Cube
Jul-12-17 06:00AM  6 Growth Stocks That Will Outlast a Bear Market Investopedia
Jul-11-17 06:30AM  Illumina to Announce Second Quarter 2017 Financial Results on Tuesday, August 1, 2017 Business Wire
Jul-05-17 04:22PM  3 Charts That Every Illumina, Inc. Investor Needs to See Motley Fool
Jul-03-17 10:56AM  Illumina Offers FDA-Approved NGS Cancer Companion Test Kit Zacks
Jul-01-17 06:44AM  Better Buy: Illumina, Inc. vs. Roche Holding Ltd. (ADR) Motley Fool
Jun-30-17 03:03PM  ETFs with exposure to Illumina, Inc. : June 30, 2017 Capital Cube
Jun-29-17 05:35PM  Illumina Announces FDA-approved Next-Generation Sequencing Cancer Companion Diagnostic Test Kit Business Wire
Jun-28-17 09:00AM  Adamas Appoints New Chief Financial Officer GlobeNewswire
Jun-26-17 03:01AM  Genomics England Adopts Illuminas BaseSpace Variant Interpreter for Cancer Business Wire
Jun-23-17 02:42PM  3 Stocks With Veeva Systems-Like Return Potential Motley Fool
08:16AM  Illumina, Inc. breached its 50 day moving average in a Bullish Manner : ILMN-US : June 23, 2017 Capital Cube
Jun-22-17 03:52PM  Illumina Shines as Another Biotech Winner
Jun-19-17 03:31PM  ETFs with exposure to Illumina, Inc. : June 19, 2017 Capital Cube
08:24AM  3 Most Wildly Overvalued Stocks in Biotech (At Least on Paper) Motley Fool
Jun-13-17 10:18AM  Coalition for Access to Prenatal Screening Announces Clinical Advisory Board PR Newswire
Jun-08-17 04:42PM  Illumina Inc. Stock History: The Genomic-Sequencing Leader's Path to Success Motley Fool
01:40PM  ETFs with exposure to Illumina, Inc. : June 8, 2017 Capital Cube
10:26AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Files Amended Complaint Against Illumina, Inc. and Senior Officers Business Wire
Jun-07-17 03:43PM  Exact Sciences Corporation: The Bear Case From a Bull Motley Fool
Jun-06-17 08:39AM  Illumina, Inc. :ILMN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017 Capital Cube
Jun-03-17 07:30AM  Grail passes early test in quest to find cancer in blood Reuters
May-31-17 04:42PM  3 Top Gene-Sequencing Stocks Poised for Solid Growth Motley Fool
01:00PM  Historically Strong Stocks in June Investopedia
May-30-17 06:30AM  Illumina to Webcast Live Presentation at the Goldman Sachs Global Healthcare Conference Business Wire
May-25-17 09:03AM  5 Top Healthcare Technology Trends That Could Make You Rich Motley Fool
May-23-17 07:22PM  Start-up Genome Medical is training experts to help you figure out what your genetic tests mean CNBC
May-22-17 11:24AM  Illumina CEO: When you invest in health research you actu... CNBC Videos
09:00AM  Illumina Names Mark Van Oene Chief Commercial Officer, Sales Leader Brings Genomics Expertise and Strong Commercial Leadership Experience to the Role Business Wire
May-15-17 05:20PM  Blood money: Peninsula liquid biopsy company gets $360M injection American City Business Journals
May-14-17 12:03PM  3 Best Stocks in Personalized Medicine Motley Fool
May-10-17 06:01PM  The Two Reasons Why Illumina Rose 8.3% In April Motley Fool
May-09-17 07:30AM  Cramer: These Sectors Look Bullish (Part III)
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array. In addition, the company provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and non-invasive prenatal testing services. It serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors. It has collaboration agreements with IBM Watson Health to access genome data interpretation by integrating Watson for genomics into Illumina's BaseSpace Sequence Hub and tumor sequencing process; and NRGene to develop new molecular breeding tools for cattle to support global food production. The company also has a co-development agreement with Munich Leukemia Laboratory GmbH and IBM Watson Health to build a cognitive technology prototype to help researchers improve leukemia treatment. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Van Oene MarkSVP Chief Commercial OfficerSep 12Option Exercise29.445,838171,87124,908Sep 14 06:05 PM
FLATLEY JAY TDirectorSep 12Option Exercise70.8220,0001,416,400539,176Sep 14 06:08 PM
FLATLEY JAY TDirectorSep 12Sale211.1120,0004,222,121519,176Sep 14 06:08 PM
Van Oene MarkSVP Chief Commercial OfficerSep 12Sale211.339,7292,056,03415,179Sep 14 06:05 PM
Ronaghi MostafaSr VP & CTOSep 07Option Exercise44.3820,000887,60086,725Sep 08 05:41 PM
Ronaghi MostafaSr VP & CTOSep 07Sale210.0020,0004,200,00066,725Sep 08 05:41 PM
Stapley MarcEVP & Chief Administrative OfcSep 05Sale205.932,000411,85734,679Sep 07 07:19 PM
Dadswell CharlesSr VP & General CounselSep 05Sale205.7114529,8288,971Sep 07 07:17 PM
Bouchard MichelChief Accounting OfficerAug 31Sale202.384,774966,17010,387Sep 01 05:34 PM
Bouchard MichelChief Accounting OfficerAug 30Sale200.00616123,20015,161Sep 01 05:34 PM
FLATLEY JAY TDirectorAug 29Option Exercise70.8220,0001,416,400539,176Aug 30 07:58 PM
FLATLEY JAY TDirectorAug 29Sale194.9320,0003,898,692519,176Aug 30 07:58 PM
FLATLEY JAY TDirectorAug 28Sale197.392,540501,370140Aug 30 07:58 PM
FLATLEY JAY TDirectorAug 15Option Exercise70.8220,0001,416,400539,176Aug 17 09:23 PM
FLATLEY JAY TDirectorAug 15Sale194.7320,0003,894,601519,176Aug 17 09:23 PM
OSTADAN OMEADEVP Ops, Products, StrategyAug 07Sale195.261,671326,27924,571Aug 09 08:39 PM
Stapley MarcEVP & Chief Administrative OfcAug 03Sale196.802,000393,60036,641Aug 07 08:32 PM
Dadswell CharlesSr VP & General CounselAug 03Sale197.001,609316,9739,037Aug 07 08:21 PM
FLATLEY JAY TDirectorAug 02Option Exercise70.825,000354,100524,176Aug 03 09:14 PM
Ronaghi MostafaSr VP & CTOAug 02Option Exercise44.3810,000443,80076,585Aug 04 05:13 PM
EASTHAM KARINDirectorAug 02Option Exercise75.6610,800817,12824,388Aug 04 05:44 PM
EASTHAM KARINDirectorAug 02Sale195.0010,8002,106,00013,588Aug 04 05:44 PM
Bouchard MichelChief Accounting OfficerAug 02Sale194.973,131610,44015,762Aug 04 05:17 PM
Ronaghi MostafaSr VP & CTOAug 02Sale195.0010,0001,950,00066,585Aug 04 05:13 PM
FLATLEY JAY TDirectorAug 02Sale188.005,000940,000519,176Aug 03 09:14 PM
FLATLEY JAY TDirectorAug 01Option Exercise70.8215,0001,062,300534,176Aug 03 09:14 PM
FLATLEY JAY TDirectorAug 01Sale172.5715,0002,588,568519,176Aug 03 09:14 PM
FLATLEY JAY TDirectorJul 18Option Exercise70.8215,0001,062,300534,176Jul 20 07:37 PM
FLATLEY JAY TDirectorJul 18Sale170.7715,0002,561,565519,176Jul 20 07:37 PM
Stapley MarcEVP & Chief Administrative OfcJul 14Sale173.562,000347,12338,641Jul 17 08:34 PM
OSTADAN OMEADEVP Ops, Products, StrategyJul 07Sale172.731,672288,80526,242Jul 11 07:29 PM
FLATLEY JAY TDirectorJul 05Option Exercise70.8215,0001,062,300534,176Jul 07 06:10 PM
FLATLEY JAY TDirectorJul 05Sale172.9215,0002,593,830519,176Jul 07 06:10 PM
Dadswell CharlesSr VP & General CounselJul 03Sale174.2414525,26510,646Jul 05 07:13 PM
Bouchard MichelChief Accounting OfficerJun 23Sale185.0024645,51018,893Jun 23 07:25 PM
FLATLEY JAY TDirectorJun 22Option Exercise70.825,000354,100524,176Jun 22 06:49 PM
FLATLEY JAY TDirectorJun 22Sale180.005,000900,000519,176Jun 22 06:49 PM
FLATLEY JAY TDirectorJun 20Option Exercise70.8215,0001,062,300534,176Jun 22 06:49 PM
FLATLEY JAY TDirectorJun 20Sale177.6115,0002,664,120519,176Jun 22 06:49 PM
Stapley MarcEVP & Chief Administrative OfcJun 12Sale170.852,000341,69940,641Jun 14 08:19 PM
Bouchard MichelChief Accounting OfficerJun 08Sale178.9124644,01219,139Jun 09 02:09 PM
FLATLEY JAY TDirectorJun 06Option Exercise36.3020,000726,000539,176Jun 08 04:43 PM
FLATLEY JAY TDirectorJun 06Sale180.2420,0003,604,878519,176Jun 08 04:43 PM
Dadswell CharlesSr VP & General CounselJun 05Sale184.7514526,78910,791Jun 07 05:26 PM
FLATLEY JAY TDirectorJun 02Sale182.001,720313,0402,680Jun 02 08:07 PM
FLATLEY JAY TDirectorJun 01Sale179.001,600286,4004,400Jun 02 08:07 PM
BRADBURY DANIELDirectorMay 25Option Exercise71.0960042,65415,924May 26 06:25 PM
ARNOLD FRANCESDirectorMay 25Sale174.77825144,1858,816May 26 06:22 PM
BRADBURY DANIELDirectorMay 25Sale173.61600104,16715,324May 26 06:25 PM
FLATLEY JAY TDirectorMay 23Option Exercise36.3015,000544,500534,176May 25 06:42 PM
FLATLEY JAY TDirectorMay 23Sale175.5315,0002,632,983519,176May 25 06:42 PM
BOWMAN A BLAINEDirectorMay 10Option Exercise75.662,300174,01818,004May 12 07:14 PM
BOWMAN A BLAINEDirectorMay 10Sale181.612,300417,71015,704May 12 07:14 PM
FLATLEY JAY TDirectorMay 09Option Exercise36.3020,000726,000539,176May 11 05:53 PM
Bouchard MichelChief Accounting OfficerMay 09Sale184.685,7401,060,03519,385May 10 08:08 PM
FLATLEY JAY TDirectorMay 09Sale184.1420,0003,682,718519,176May 11 05:53 PM
OSTADAN OMEADEVP Ops, Products, StrategyMay 08Sale186.101,672311,15927,914May 10 04:20 PM
Dadswell CharlesSr VP & General CounselMay 03Sale187.071,609300,99610,936May 05 07:52 PM
BOWMAN A BLAINEDirectorApr 12Option Exercise75.663,000226,98018,704Apr 13 06:40 PM
BOWMAN A BLAINEDirectorApr 12Sale172.723,000518,15115,704Apr 13 06:40 PM
BRADBURY DANIELDirectorApr 07Option Exercise71.0960042,65417,065Apr 11 08:16 PM
BRADBURY DANIELDirectorApr 07Sale172.79600103,67516,465Apr 11 08:16 PM
OSTADAN OMEADEVP Ops, Products, StrategyMar 24Sale170.001,672284,24029,586Mar 28 07:05 PM
BRADBURY DANIELDirectorMar 21Option Exercise71.0960042,65417,065Mar 23 02:14 PM
BRADBURY DANIELDirectorMar 21Sale163.5660098,13416,465Mar 23 02:14 PM
BOWMAN A BLAINEDirectorMar 08Option Exercise75.663,000226,98018,704Mar 10 07:41 PM
BOWMAN A BLAINEDirectorMar 08Sale164.883,000494,63315,704Mar 10 07:41 PM
BRADBURY DANIELDirectorFeb 17Option Exercise71.0960042,65417,065Feb 21 09:05 PM
BRADBURY DANIELDirectorFeb 17Sale162.8060097,67716,465Feb 21 09:05 PM
Bouchard MichelChief Accounting OfficerFeb 15Option Exercise0.002,625025,292Feb 17 08:11 PM
deSouza Francis APresident and CEOFeb 15Option Exercise0.0014,318082,523Feb 17 09:05 PM
Stapley MarcEVP & Chief Administrative OfcFeb 15Option Exercise0.008,438044,423Feb 17 08:51 PM
Ronaghi MostafaSr VP & CTOFeb 15Option Exercise0.007,032067,922Feb 17 08:45 PM
FLATLEY JAY TDirectorFeb 15Option Exercise0.0028,5100527,236Feb 17 08:37 PM
Dadswell CharlesSr VP & General CounselFeb 15Option Exercise0.007,032014,699Feb 17 08:22 PM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 15Option Exercise0.008,438033,009Feb 17 08:16 PM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 13Sale163.102,173354,41624,571Feb 15 07:42 PM
BOWMAN A BLAINEDirectorFeb 08Option Exercise70.193,000210,56018,704Feb 10 03:55 PM
BOWMAN A BLAINEDirectorFeb 08Sale162.743,000488,23115,704Feb 10 03:55 PM
Dadswell CharlesSr VP & General CounselFeb 06Sale161.2657292,2417,592Feb 08 07:39 PM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 02Sale160.411,104177,09326,586Feb 06 08:17 PM
OSTADAN OMEADEVP Ops, Products, StrategyJan 30Sale160.9025941,67327,690Jan 31 07:31 PM
OSTADAN OMEADEVP Ops, Products, StrategyJan 19Sale160.3537860,61228,662Jan 19 05:56 PM
OSTADAN OMEADEVP Ops, Products, StrategyJan 17Sale160.002,000320,00029,040Jan 19 05:56 PM
BOWMAN A BLAINEDirectorJan 11Option Exercise42.823,000128,46018,704Jan 13 07:05 PM
BOWMAN A BLAINEDirectorJan 11Sale162.893,000488,65815,704Jan 13 07:05 PM
Dadswell CharlesSr VP & General CounselJan 10Sale161.6011618,7468,420Jan 12 09:36 PM
BRADBURY DANIELDirectorJan 04Option Exercise71.0960042,65417,065Jan 06 06:59 PM
BRADBURY DANIELDirectorJan 04Sale135.0160081,00816,465Jan 06 06:59 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 15Sale126.162,000252,32031,040Dec 19 08:08 PM
BRADBURY DANIELDirectorDec 12Option Exercise71.0960042,65417,065Dec 14 08:09 PM
BRADBURY DANIELDirectorDec 12Sale123.4260074,05416,465Dec 14 08:09 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 08Sale121.633,000364,89052,988Dec 09 04:18 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 01Sale133.303,000399,90051,492Dec 05 06:41 PM
BRADBURY DANIELDirectorNov 14Option Exercise71.0960042,65417,065Nov 15 06:14 PM
BRADBURY DANIELDirectorNov 14Sale136.3460081,80316,465Nov 15 06:14 PM
BRADBURY DANIELDirectorOct 07Option Exercise71.0960042,65417,065Oct 11 08:35 PM
BRADBURY DANIELDirectorOct 07Sale184.36600110,61316,465Oct 11 08:35 PM
Dadswell CharlesSr VP & General CounselOct 04Sale182.3811621,15639,900Oct 06 05:32 PM
EPSTEIN ROBERT SDirectorSep 20Sale174.2930052,2876,924Sep 21 06:56 PM